TrialCurveNEOCRTEC5010: reconstructed Kaplan–Meier curves
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | J Clin Oncol. 2018 Aug 8;36(27):2796–803. doi: 10.1200/JCO.2018.79.1483 |
|---|---|
| DOI | 10.1200/JCO.2018.79.1483 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Overall survival — Intention-to-treat population
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Group CRT 71.5 months; Group S 66.3 months. Survival at 18 months: Group CRT 82%; Group S 78%. Hazard ratio Group S vs Group CRT 1.34 (95% CI 1.00–1.79).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Group CRT | 224 | 83 | 71.5 |
| Group S | 227 | 104 | 66.3 |
- Group S vs Group CRT: reconstructed HR 1.34 (95% CI 1.00–1.79)
Landmark survival (reconstructed)
| Time | Group CRT | Group S |
|---|---|---|
| 6 mo | 98.2% | 95.1% |
| 12 mo | 87.1% | 86.2% |
| 18 mo | 82.1% | 77.6% |
| 24 mo | 76.1% | 72.6% |
| 36 mo | 69.9% | 59.2% |
| 48 mo | 67.9% | 53.3% |
| 60 mo | 61.8% | 50.9% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.71, reconstructed 0.746 pass
Disease-free survival — Patients after R0 resection
From figure panel B · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Group CRT 100.6 months; Group S 41.8 months. Survival at 18 months: Group CRT 79%; Group S 65%. Hazard ratio Group CRT vs Group S 0.57 (95% CI 0.42–0.78).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Group CRT | 182 | 66 | 100.6 |
| Group S | 207 | 108 | 41.8 |
- Group CRT vs Group S: reconstructed HR 0.57 (95% CI 0.42–0.78)
Landmark survival (reconstructed)
| Time | Group CRT | Group S |
|---|---|---|
| 6 mo | 98.3% | 89.8% |
| 12 mo | 86.1% | 75.1% |
| 18 mo | 79.4% | 64.8% |
| 24 mo | 77.7% | 59.8% |
| 36 mo | 71.1% | 51.9% |
| 48 mo | 67.6% | 48.1% |
| 60 mo | 62.6% | 45.5% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.58, reconstructed 0.572 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/neocrtec5010-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/neocrtec5010-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: J Clin Oncol. 2018 Aug 8;36(27):2796–803. doi: 10.1200/JCO.2018.79.1483 doi:10.1200/JCO.2018.79.1483. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/neocrtec5010
Report a problem with these data
Related trials
- NEOCRTEC5010 (long-term follow-up): Disease-free survival; Overall survival
- Neoadjuvant chemoradiotherapy vs adjuvant therapy in ESCC: Disease-free survival; Overall survival
- CheckMate 648 (Japanese subgroup): Duration of response per BICR; Overall survival; Progression-free survival per BICR
- CheckMate 648: Duration of response (per BICR); Overall survival; Progression-free survival (per BICR)
- RATIONALE-306 (Japanese subgroup, 3-year): Overall survival; Progression-free survival (investigator assessment)
- Chemoradiotherapy with S-1 in older patients with esophageal cancer: Overall survival; Progression-free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials